News
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin...
Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at ICAAC/ICC...
News
Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab)...
Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer...
News
New pre-clinical data shows Alcon’s pre-loaded IOL delivery system...
Data presented at ESCRS shows UltraSert™ Pre-loaded IOL Delivery System created the least corneal incision enlargement and the lowest final incision size versus two commonly...
News
Regional variations in US cancer imaging data: a warning...
Danil V Makarov speaks to Gemma Westcott, Commissioning Editor: Danil V Makarov is an Assistant Professor and Director of Surgical Research in the Department of...
News
Merck and Tridonic Enter Into License Agreement for White...
Merck, a leading company for innovative and top-quality high-tech products in the healthcare, life science and performance materials sectors, announced today that it has entered...
News
Adjuvant HER2/neu peptide cancer vaccines in breast cancer
Active cancer/peptide cancer immunotherapy remains an exciting and rapidly advancing field in oncology. Peptide cancer vaccines are an attractive therapeutic option as they...
News
Pfizer Completes Acquisition of Hospira
Ian Read, chairman and chief executive officer, Pfizer Said, We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.